GeoVax Labs, Inc. (Nasdaq: GOVX) announced that Senthil Ranganathan, PhD, Vice President, Technical Development and CMC Operations, will present at the World Vaccine Congress Europe 2026, taking place October 19–22 at the RAI Amsterdam. The presentation, titled “Revolutionizing MVA – Single Dose and Continuous Cell-Line Manufacturing,” will highlight the company’s progress in advancing next-generation Modified Vaccinia Ankara (MVA) technologies. These developments matter because they could overcome longstanding limitations of MVA-based vaccines, which have historically required multiple doses and manufacturing processes dependent on primary avian cells. By addressing both challenges, GeoVax aims to make MVA vaccines more practical for widespread use, particularly during outbreaks and biodefense emergencies.
MVA is a well-characterized vaccine platform with a decades-long history, but its broader deployment has been constrained by multi-dose regimens and manufacturing that relies on chicken embryo fibroblasts (CEF). GeoVax’s next-generation MVA-X technology is designed to enhance immune responses and enable effective vaccination after a single administration. Preclinical studies have shown protective immune responses following a single dose, and earlier this year, data presented at the World Vaccine Congress Washington demonstrated that a single administration of MVA-X achieved protective efficacy comparable to a traditional two-dose MVA regimen in a murine orthopoxvirus challenge model, with protection maintained through Day 150. This suggests that MVA-X could simplify vaccination campaigns, improve compliance, and allow for faster deployment during public health emergencies.
In parallel, GeoVax is advancing a continuous cell-line manufacturing approach using the AGE1.CR.pIX avian cell line as an alternative to traditional CEF-based production. The company has demonstrated proof-of-concept for the upstream process, and the downstream process is in development to support production at the 200-liter scale, with a pathway toward 500-liter and larger-scale manufacturing. This method is designed to enable scalable and reproducible production, reduce reliance on primary-cell supply chains, and facilitate technology transfer. Continuous cell-line manufacturing could provide a more flexible foundation for rapidly increasing MVA vaccine production in response to emerging infectious diseases and biodefense requirements.
Together, these advances represent a potential evolution of the MVA platform—from conventional multi-dose vaccination and primary-cell manufacturing toward single-dose immunization supported by scalable continuous cell-line production. David A. Dodd, Chairman and Chief Executive Officer of GeoVax, commented, “MVA is an important and well-established vaccine platform, and we believe there are significant opportunities to further improve how MVA-based vaccines are administered and manufactured. Our work with MVA-X and AGE1.CR.pIX addresses both sides of that equation—potentially simplifying vaccination through a single-dose approach while establishing a scalable manufacturing platform capable of supporting broader and more responsive vaccine supply.” Dodd continued, “Senthil’s participation in the Platform Technologies workshop at World Vaccine Congress Europe provides an important opportunity to share GeoVax’s progress with the global vaccine community. Bringing together next-generation vaccine design and scalable manufacturing has potentially important implications for outbreak response, pandemic preparedness, biodefense, strategic stockpiling, and expanded global access to MVA-based vaccines.”
The implications of these developments extend beyond GeoVax’s pipeline. A single-dose MVA vaccine could significantly reduce logistical hurdles in mass vaccination campaigns, especially in resource-limited settings or during sudden outbreaks. Meanwhile, a continuous cell-line manufacturing platform could alleviate bottlenecks in vaccine production, making it easier to scale up supply quickly. This is particularly relevant for biodefense, where rapid response to threats like smallpox or mpox is critical. GeoVax’s priority program, GEO-MVA, is an MVA-based vaccine targeting mpox and smallpox, advancing under an expedited regulatory pathway with plans to initiate a pivotal Phase 3 clinical trial in the second half of 2026. The manufacturing innovations presented at the conference could directly support that program and others.
For more information, visit www.geovax.com. The presentation will take place on Monday, October 19, 2026, at 11:00 a.m. in the Platform Technologies workshop track. This news was originally distributed by NEWMEDIAWIRE.
